TRPTI supplement and gut hormone GLP-1 in overweight or obese adults
Tests whether the supplement TRPTI changes GLP-1 levels in overweight adults.
Plain-language title generated from the registry record
Registry title: TRPTI Metabolic and GLP-1 Pharmacodynamic Study
Key facts
- Where
- Fortitude Valley, AustraliaSee the site
- Phase
- Phase 4
Where in Australia
- RDC ClinicalFortitude Valley, AustraliaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- RDC Clinical Pty Ltd
- Trial code
- NCT07850466
- Record updated
- 30 September 2026
- Original description
The goal of this clinical trial is to assess whether TRPTI™ supplementation affects GLP-1 and related metabolic markers in generally healthy adults who are overweight or obese (BMI 25.0-34.9 kg/m², aged 30 years and older).Read full original descriptionShow less
Short-term Effect of TRPTI Supplementation on GLP-1 and Related Metabolic Markers in Overweight or Obese Adults - a Double-blind, Randomised, Placebo-controlled, Two-arm Cross-over Study
The goal of this clinical trial is to assess whether TRPTI™ supplementation affects GLP-1 and related metabolic markers in generally healthy adults who are overweight or obese (BMI 25.0-34.9 kg/m², aged 30 years and older).
Researchers will compare TRPTI™ 150 mg to a matching placebo capsule to see if TRPTI™ produces a meaningful difference in GLP-1 response and associated metabolic and appetite-related markers over 8 hours.
Participants will attend two 9-hour clinic visits (crossover design, with a minimum 6-day washout between visits).
Inclusion: Adults aged 30 years and older; Generally healthy; BMI 25.0-34.9 kg/m²; Able to provide informed consent; Agree to not participate in another clinical trial while enrolled in this trial; Agree not to change current diet and/or exercise frequency or intensity during entire study period; Females using a prescribed form of birth control (e.g., oral contraceptive); Participant's ability to participate fully and comply with demands of the study including attendance at all scheduled blood collection time points; Able to attend the clinic on all required days.
Exclusion: Current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years; Active smokers, nicotine use or drug (prescription or illegal substances) abuse; Have a serious illness e.g., neurological disorders such as MS, kidney disease, liver disease or heart conditions; Have an unstable illness e.g., thyroid gland dysfunction, uncontrolled mood disorders (e.g., depression, anxiety, bipolar); Diagnosed with any known metabolic or endocrine dysfunctions e.g., diabetes, NAFLD, hyperinsulinaemia, hypoglycaemia; Allergic to any of the ingredients in active or placebo formula; Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion; History of any glucose or insulin regulation problem, including diabetes; Use of any medication or supplements that may affect any metabolic pathway associated with satiety (e.g., GLP-1, GIP, glucagon), glucose or insulin; Significant change in diet in the past 1 month (e.g., removal of a food group or calorie restriction); Chronic past and/or current alcohol use (>21 alcoholic drinks/week); Pregnant or lactating women; Participants who are or who have participated in any other clinical trial during the past 1 month (excludes RDC clinical trials which are to be assessed on a case-by-case basis); Regular use within the past 4 weeks of supplements containing OEA and LipiSperse (TRPTITM).